CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

From TechCrunch

By Aisha Malik

November 15, 2023

Inito, a startup that helps women quickly track fertility hormones at home, raises $6M

Inito, a YC alum that helps women track fertility hormones quickly at home, has raised $6 million in Series A funding led by Fireside Ventures. The startup’s fertility monitor and kit is designed to give users easy-to-read fertility diagnostic results directly on their phone in just 10 minutes. The Bengaluru, India-based startup was founded in […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Most Recent

Startup Abby Care raises $82 million to turn family members into paid caregivers

As a kid, Havi Nguyen sometimes missed school to translate at doctor's appointments, and was managing Medicaid paperwork for her family, who had recently immigrated from Vietnam.

Oct 18, 2026

795 accounts funded by ADI Predictstreet's own fee-collecting wallet drove 99% of the FIFA-partnered prediction market's activity since late August

ADI Predictstreet, backed by Abu Dhabi's royal family, paid close to $150 million for advertising rights during the World Cup

Oct 18, 2026

China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround

CXMT shares fell over 6% on Monday after the company released its earnings forecast for the first nine months of 2026.

Oct 18, 2026

World launches World ID suite for banks, makes Zoom deepfake check generally available

The identity project co-founded by OpenAI CEO Sam Altman named Bain Capital and VanEck Funds among its design partners but did not name a bank that has started using the product.

Oct 18, 2026

Similar Posts

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

Startup Evvy raises $40M to accelerate precision diagnostics and medicine for women’s health

Evvy, an artificial intelligence startup that’s looking to enhance women’s healthcare, said today it has closed on $40 million in Series B funding to scale its precision diagnostics and care platform. The round was led by Catalio Capital Management, with new investors including the U.S. Fertility In

Sep 15, 2026

Evvy raises $40M as it seeks to further women’s health research with vaginal microbiome data

Women’s health company Evvy on Tuesday said it has raised a $40 million Series B led by Catalio Capital Management. Launched in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, the company is best known for operating what it touts as the world’s only at-home CLIA-certified and CLEP-certified m

Sep 15, 2026

Backed With $6M, Max Levchin's Glow App For Tracking Female Fertility Debuts

Glow, the fertility tracking iOS app co-founded by Max Levchin, debuts in the App Store with $6M backing from Founders Fund and Andreessen Horowitz, introducing the Glow First fund to help cover fertility treatments.

Aug 7, 2013